|1.||Carides, Alexandra D: 14 articles (02/2013 - 06/2002)|
|2.||Evans, Judith K: 12 articles (02/2009 - 06/2002)|
|3.||Muñoz, Miguel: 11 articles (10/2014 - 04/2010)|
|4.||Hesketh, Paul J: 11 articles (03/2012 - 05/2003)|
|5.||Petty, Kevin J: 11 articles (07/2006 - 05/2003)|
|6.||Navari, Rudolph M: 10 articles (01/2015 - 06/2002)|
|7.||Coveñas, Rafael: 9 articles (10/2014 - 08/2010)|
|8.||Gralla, Richard J: 9 articles (11/2012 - 05/2003)|
|9.||Horgan, Kevin J: 9 articles (05/2007 - 05/2003)|
|10.||Grunberg, Steven M: 8 articles (11/2010 - 05/2003)|
02/01/2004 - "Two pivotal phase III trials enrolling a total of 1099 patients showed that the complete control of emesis improved by 20% in patients receiving aprepitant as compared with standard therapy, with the most impressive differences being in delayed emesis. "
07/01/2011 - "Vomiting was dramatically reduced by the concomitant administration of aprepitant. "
01/01/2013 - "Patients aged 65 and over have a significantly greater chance of experiencing a complete response (no vomiting or use of rescue therapy) to antiemetic treatment when aprepitant is included in the antiemetic regimen (Risk Ratio 1.25, 95% Confidence Interval 1.11 to 1.40, p=0.0002) than when it is not. "
06/01/2011 - "Aprepitant markedly improved control of emesis in patients with one or more risk factors. "
04/01/2010 - "The aprepitant regimen provided superior efficacy in the treatment of CINV in a broad range of patients receiving MEC (non-AC or AC) in both no vomiting and complete response endpoints. "
02/01/2012 - "Multiple-day dosing of aprepitant was effective for prevention of nausea(Odds ratio: 0. "
10/01/2007 - "Post hoc analyses of pooled data from these trials were performed to more fully characterize the efficacy profile of aprepitant in terms of nausea and use of rescue therapy. "
08/01/2015 - "Furthermore maximum nausea was 1.58 ± 1.91 in the control group and 0.73 ± 1.79 in the aprepitant group (P=.084); for the head-and-neck subset, 2.23 ± 2.13 in the control group and 0.64 ± 1.77 in the aprepitant group, respectively (P=.03). "
07/01/2015 - "The aprepitant group also had statistically significantly higher percentages of no significant nausea, complete response and complete protection than the control group overall. "
01/01/2015 - "Nausea was significantly more severe in 3 days regimen of aprepitant than in 6 days regimen. "
|3.||Postoperative Nausea and Vomiting (PONV)
05/01/2015 - " data suggested that NK-1R antagonists, especially aprepitant were effective in preventing PONV compared with placebo. "
01/01/2009 - "A single oral dose of aprepitant 40 mg administered prior to patients undergoing abdominal surgery was also effective in the prevention of postoperative nausea and vomiting (PONV). "
09/01/2010 - "Aprepitant reduced the percentage of patients with PONV (39% of study and 70% of control patients). "
10/01/2007 - "Preventing postoperative nausea and vomiting: post hoc analysis of pooled data from two randomized active-controlled trials of aprepitant."
10/01/2015 - "It is recommended that aprepitant is used to treat patients at risk for PONV and for whom PONV could lead to catastrophic adverse outcomes."
04/01/2010 - "This study assessed aprepitant in patients receiving a broad range of MEC regimens with a variety of tumor types. "
12/01/2014 - "To our knowledge, this is the first case report to document the effects of aprepitant in cancer patients receiving anticoagulation therapy."
11/01/2014 - "The aprepitant-treated and untreated groups were comparable in mean age (56.3 vs 58.1 years), male gender (82.3% vs 86.3%), tumor location, and number of metastatic sites. "
06/01/2014 - "Medical records of patients with cancer receiving IV fosaprepitant through a peripheral line were reviewed. "
03/07/2014 - "Administration of Emend IV was found to decrease tumor volume and decrease cellular proliferation indicating that SP may play a role in tumor pathogenesis within the brain. "
|5.||Breast Neoplasms (Breast Cancer)
10/01/2014 - "No in-depth studies of the involvement of this system in breast cancer (BC) have been carried out, and the action exerted by the drug aprepitant on BC cells is currently unknown. "
02/01/2009 - "This is a single center, randomized, double-blind placebo-controlled study to evaluate the NK(1)-receptor antagonist, aprepitant, in Chinese breast cancer patients. "
08/01/2011 - "[Efficacy and safety of aprepitant in patients with breast cancer]."
01/01/2013 - "The results of this study suggest that aprepitant is cost-effective for preventing CINV associated with chemotherapy for patients with breast cancer in the UK health care setting."
02/01/2013 - "For MEC-treated patients, complete response rates were also higher for aprepitant patients than active-control patients for all tumor types, with a significant difference noted among patients with breast cancer (54.9% vs 43.9%, P<0.0001). "
|3.||Neurokinin-1 Receptors (Neurokinin 1 Receptor)
|8.||Serotonin (5 Hydroxytryptamine)
|9.||5-HT3 Serotonin Receptors (5 HT3 Receptor)
|10.||Serotonin 5-HT3 Receptor Antagonists
|1.||Drug Therapy (Chemotherapy)
|3.||Hematopoietic Stem Cell Transplantation